← Back to all trials
Active Not Recruiting
NCT07327840
Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)
Conditions: Lipoprotein Disorder
Sex: All
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 204
Sponsor: Kylonova (Xiamen) Biopharma co., LTD.
Location: Alliance Clinical - Los Angeles Los Angeles California
Summary
This is a phase 2, double-blind, randomized, placebo-controlled, multi-center, dose-finding study to evaluate the efficacy and safety of Kylo-11 administered subcutaneously compared to placebo in participants with ASCVD and elevated Lp(a).
Eligibility Criteria
Inclusion Criteria:
* Age 18 to 80 years
* Clinical diagnosis of atherosclerotic cardiovascular disease with elevated Lp(a)
* Other inclusion criteria applied per protocol.
Exclusion Criteria:
* Have moderate to severe heart failure (New York Heart Association \[NYHA\] Functional Classification III or IV during Screening) or last known left ventricular ejection fraction \
Source: ClinicalTrials.gov (NCT07327840). StuddyBuddy aggregates publicly available trial information.
